<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     General<BR>                     <BR>                        The recommended dose of XELODA was determined in an open-label, randomized clinical study, exploring the efficacy and safety of continuous therapy with capecitabine (1331 mg/m2/day in two divided doses, n=39), intermittent therapy with capecitabine (2510 mg/m2/day in two divided doses, n=34), and intermittent therapy with capecitabine in combination with oral leucovorin (LV) (capecitabine 1657 mg/m2/day in two divided doses, n=35; leucovorin 60 mg/day) in patients with advanced and/or metastatic colorectal carcinoma in the first-line metastatic setting. There was no apparent advantage in response rate to adding leucovorin to XELODA; however, toxicity was increased. XELODA, 1250 mg/m2 twice daily for 14 days followed by a 1-week rest, was selected for further clinical development based on the overall safety and efficacy profile of the three schedules studied.<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Adjuvant Colon Cancer<BR>                     <BR>                        A multicenter randomized, controlled phase 3 clinical trial in patients with Dukes' C colon cancer provided data concerning the use of XELODA for the adjuvant treatment of patients with colon cancer. The primary objective of the study was to compare disease-free survival (DFS) in patients receiving XELODA to those receiving IV 5-FU/LV alone. In this trial, 1987 patients were randomized either to treatment with XELODA 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks) or IV bolus 5-FU 425 mg/m2 and 20 mg/m2 IV leucovorin on days 1 to 5, given as 4-week cycles for a total of 6 cycles (24 weeks). Patients in the study were required to be between 18 and 75 years of age with histologically-confirmed Dukes' stage C colon cancer with at least one positive lymph node and to have undergone (within 8 weeks prior to randomization) complete resection of the primary tumor without macroscopic or microscopic evidence of remaining tumor. Patients were also required to have no prior cytotoxic chemotherapy or immunotherapy (except steroids), and have an ECOG performance status of 0 or 1 (KPS ≥ 70%), ANC ≥ 1.5×109/L, platelets ≥ 100×109/L, serum creatinine ≤ 1.5 ULN, total bilirubin ≤ 1.5 ULN, AST/ALT ≤ 2.5 ULN and CEA within normal limits at time of randomization.<BR>                        The baseline demographics for XELODA and 5-FU/LV patients are shown in <BR>                              Table 1<BR>                           . The baseline characteristics were well-balanced between arms. <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t1" width="75%"><BR>                           <caption>Table 1 Baseline Demographics</caption><BR>                           <col align="left" width="50%" valign="middle"/><BR>                           <col align="center" width="25%" valign="middle"/><BR>                           <col align="center" width="25%" valign="middle"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule">XELODA<br/>(n=1004)</th><BR>                                 <th styleCode="Lrule Rrule">5-FU/LV<br/>(n=983)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule">Age (median, years)</td><BR>                                 <td styleCode="Lrule">62</td><BR>                                 <td styleCode="Lrule Rrule">63</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Range</td><BR>                                 <td styleCode="Lrule Botrule">(25-80)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">(22-82)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Gender</td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Male (n, %)</td><BR>                                 <td styleCode="Lrule">542 (54)</td><BR>                                 <td styleCode="Lrule Rrule">532 (54)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Female (n, %)</td><BR>                                 <td styleCode="Lrule Botrule">461 (46)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">451 (46)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">ECOG PS</td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;0 (n, %)</td><BR>                                 <td styleCode="Lrule">849 (85)</td><BR>                                 <td styleCode="Lrule Rrule">830 (85)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;1 (n, %)</td><BR>                                 <td styleCode="Lrule Botrule">152 (15)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">147 (15)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Staging &#8211; Primary Tumor</td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;PT1 (n, %)</td><BR>                                 <td styleCode="Lrule">12 (1)</td><BR>                                 <td styleCode="Lrule Rrule">6 (0.6)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;PT2 (n, %)</td><BR>                                 <td styleCode="Lrule">90 (9)</td><BR>                                 <td styleCode="Lrule Rrule">92 (9)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;PT3 (n, %)</td><BR>                                 <td styleCode="Lrule">763 (76)</td><BR>                                 <td styleCode="Lrule Rrule">746 (76)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;PT4 (n, %)</td><BR>                                 <td styleCode="Lrule">138 (14)</td><BR>                                 <td styleCode="Lrule Rrule">139 (14)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Other (n, %)</td><BR>                                 <td styleCode="Lrule Botrule">1 (0.1)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">0 (0)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Staging &#8211; Lymph Node</td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;pN1 (n, %)</td><BR>                                 <td styleCode="Lrule">695 (69)</td><BR>                                 <td styleCode="Lrule Rrule">694 (71)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;pN2 (n, %)</td><BR>                                 <td styleCode="Lrule">305 (30)</td><BR>                                 <td styleCode="Lrule Rrule">288 (29)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Other (n, %)</td><BR>                                 <td styleCode="Lrule Botrule">4 (0.4)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">1 (0.1)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>All patients with normal renal function or mild renal impairment began treatment at the full starting dose of 1250 mg/m2 orally twice daily. The starting dose was reduced in patients with moderate renal impairment (calculated creatinine clearance 30 to 50 mL/min) at baseline (see <BR>                              DOSAGE AND ADMINISTRATION<BR>                           ). Subsequently, for all patients, doses were adjusted when needed according to toxicity. Dose management for XELODA included dose reductions, cycle delays and treatment interruptions (see <BR>                              Table 2<BR>                           ).<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t2" width="75%"><BR>                           <caption>Table 2 Summary of Dose Modifications in X-ACT Study</caption><BR>                           <col align="left" valign="top" width="60%"/><BR>                           <col align="center" valign="top" width="20%"/><BR>                           <col align="center" valign="top" width="20%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule">XELODA<br/>N = 995</th><BR>                                 <th styleCode="Lrule Rrule">5-FU/LV<br/>N = 974</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Median relative dose intensity (%)</td><BR>                                 <td styleCode="Lrule Botrule">93</td><BR>                                 <td styleCode="Lrule Botrule Rrule">92</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Patients completing full course of treatment (%)</td><BR>                                 <td styleCode="Lrule Botrule">83</td><BR>                                 <td styleCode="Lrule Botrule Rrule">87</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Patients with treatment interruption (%)</td><BR>                                 <td styleCode="Lrule Botrule">15</td><BR>                                 <td styleCode="Lrule Botrule Rrule">5</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Patients with cycle delay (%)</td><BR>                                 <td styleCode="Lrule Botrule">46</td><BR>                                 <td styleCode="Lrule Botrule Rrule">29</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Patients with dose reduction (%)</td><BR>                                 <td styleCode="Lrule Botrule">42</td><BR>                                 <td styleCode="Lrule Botrule Rrule">44</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Patients with treatment interruption, cycle delay, or dose reduction (%)</td><BR>                                 <td styleCode="Lrule Botrule">57</td><BR>                                 <td styleCode="Lrule Botrule Rrule">52</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The median follow-up at the time of the analysis was 53 months. The hazard ratio for DFS for XELODA compared to 5-FU/LV was 0.87 (95% C.I. 0.76 – 1.00). Because the upper 2-sided 95% confidence limit of hazard ratio was less than 1.20, XELODA was non-inferior to 5-FU/LV. The choice of the non-inferiority margin of 1.20 corresponds to the retention of approximately 75% of the 5-FU/LV effect on DFS. <BR>                        Survival data were not mature at the time of the analysis with a median follow-up of 53 months. The comparison of overall survival did not reach statistical significance for the test of difference (HR 0.88, 95% C.I. 0.74 – 1.05; p = 0.169).<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%"><BR>                           <caption>Table 3 Efficacy of XELODA vs 5-FU/LV in Adjuvant Treatment of Colon Cancer<footnote>Approximately 85% had 3-year DFS information</footnote><BR>                           </caption><BR>                           <col align="left" valign="top" width="50%"/><BR>                           <col align="center" valign="top" width="25%"/><BR>                           <col align="center" valign="top" width="25%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"><BR>                                    <content styleCode="italics">All Randomized Population</content><BR>                                 </th><BR>                                 <th styleCode="Lrule">XELODA<br/>(n=1004)</th><BR>                                 <th styleCode="Lrule Rrule">5-FU/LV<br/>(n=983)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold">Median follow-up (months)</content><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule">53</td><BR>                                 <td styleCode="Lrule Botrule Rrule">53</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold">3-year Disease-free Survival Rates</content><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">66.0</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">62.9</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Hazard Ratio<br/>(XELODA/5-FU/LV)<br/>(95% C.I. for Hazard Ratio),<br/>p-value<footnote>Log-rank test for differences of XELODA vs 5-FU/LV</footnote><BR>                                 </td><BR>                                 <td colspan="2" styleCode="Lrule Botrule Rrule" valign="bottom">0.87<br/>(0.76 &#8211; 1.00)<br/>p = 0.055</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Figure 1 Kaplan-Meier Estimates of Disease-Free Survival (All Randomized Population)<BR>                                 XELODA has been demonstrated to be non-inferior to 5-FU/LV.<BR>                              <BR>                           <BR>                        <BR>                        <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Metastatic Colorectal Cancer<BR>                     <BR>                        Data from two open-label, multicenter, randomized, controlled clinical trials involving 1207 patients support the use of XELODA in the first-line treatment of patients with metastatic colorectal carcinoma. The two clinical studies were identical in design and were conducted in 120 centers in different countries. Study 1 was conducted in the US, Canada, Mexico, and Brazil; Study 2 was conducted in Europe, Israel, Australia, New Zealand, and Taiwan. Altogether, in both trials, 603 patients were randomized to treatment with XELODA at a dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles; 604 patients were randomized to treatment with 5-FU and leucovorin (20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU, on days 1 to 5, every 28 days).<BR>                        In both trials, overall survival, time to progression and response rate (complete plus partial responses) were assessed. Responses were defined by the World Health Organization criteria and submitted to a blinded independent review committee (IRC). Differences in assessments between the investigator and IRC were reconciled by the sponsor, blinded to treatment arm, according to a specified algorithm. Survival was assessed based on a non-inferiority analysis.<BR>                        The baseline demographics for XELODA and 5-FU/LV patients are shown in <BR>                              Table 4<BR>                           .<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t4" width="100%"><BR>                           <caption>Table 4 Baseline Demographics of Controlled Colorectal Trials</caption><BR>                           <col align="left" width="28%" valign="middle"/><BR>                           <col align="center" width="18%" valign="middle"/><BR>                           <col align="center" width="18%" valign="middle"/><BR>                           <col align="center" width="18%" valign="middle"/><BR>                           <col align="center" width="18%" valign="middle"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th colspan="2" styleCode="Lrule">Study 1</th><BR>                                 <th colspan="2" styleCode="Lrule Rrule">Study 2</th><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Lrule Toprule"/><BR>                                 <th styleCode="Lrule Toprule">XELODA<br/>(n=302)</th><BR>                                 <th styleCode="Lrule Toprule">5-FU/LV<br/>(n=303)</th><BR>                                 <th styleCode="Lrule Toprule">XELODA<br/>(n=301)</th><BR>                                 <th styleCode="Lrule Toprule Rrule">5-FU/LV<br/>(n=301)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule">Age (median, years)</td><BR>                                 <td styleCode="Lrule">64</td><BR>                                 <td styleCode="Lrule">63</td><BR>                                 <td styleCode="Lrule">64</td><BR>                                 <td styleCode="Lrule Rrule">64</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Range</td><BR>                                 <td styleCode="Lrule Botrule">(23-86)</td><BR>                                 <td styleCode="Lrule Botrule">(24-87)</td><BR>                                 <td styleCode="Lrule Botrule">(29-84)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">(36-86)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Gender</td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Male (%)</td><BR>                                 <td styleCode="Lrule">181 (60)</td><BR>                                 <td styleCode="Lrule">197 (65)</td><BR>                                 <td styleCode="Lrule">172 (57)</td><BR>                                 <td styleCode="Lrule Rrule">173 (57)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Female (%)</td><BR>                                 <td styleCode="Lrule Botrule">121 (40)</td><BR>                                 <td styleCode="Lrule Botrule">106 (35)</td><BR>                                 <td styleCode="Lrule Botrule">129 (43)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">128 (43)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Karnofsky PS (median)</td><BR>                                 <td styleCode="Lrule">90</td><BR>                                 <td styleCode="Lrule">90</td><BR>                                 <td styleCode="Lrule">90</td><BR>                                 <td styleCode="Lrule Rrule">90</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Range</td><BR>                                 <td styleCode="Lrule Botrule">(70-100)</td><BR>                                 <td styleCode="Lrule Botrule">(70-100)</td><BR>                                 <td styleCode="Lrule Botrule">(70-100)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">(70-100)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Colon (%)</td><BR>                                 <td styleCode="Lrule">222 (74)</td><BR>                                 <td styleCode="Lrule">232 (77)</td><BR>                                 <td styleCode="Lrule">199 (66)</td><BR>                                 <td styleCode="Lrule Rrule">196 (65)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Rectum (%)</td><BR>                                 <td styleCode="Lrule Botrule">79 (26)</td><BR>                                 <td styleCode="Lrule Botrule">70 (23)</td><BR>                                 <td styleCode="Lrule Botrule">101 (34)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">105 (35)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Prior radiation therapy (%)</td><BR>                                 <td styleCode="Lrule Botrule">52 (17)</td><BR>                                 <td styleCode="Lrule Botrule">62 (21)</td><BR>                                 <td styleCode="Lrule Botrule">42 (14)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">42 (14)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Prior adjuvant 5-FU (%)</td><BR>                                 <td styleCode="Lrule Botrule">84 (28)</td><BR>                                 <td styleCode="Lrule Botrule">110 (36)</td><BR>                                 <td styleCode="Lrule Botrule">56 (19)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">41 (14)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The efficacy endpoints for the two phase 3 trials are shown in <BR>                              Table 5<BR>                            and <BR>                              Table 6<BR>                           .<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t5" width="75%"><BR>                           <caption>Table 5 Efficacy of XELODA vs 5-FU/LV in Colorectal Cancer (Study 1)</caption><BR>                           <col align="left" width="50%" valign="middle"/><BR>                           <col align="center" width="25%" valign="middle"/><BR>                           <col align="center" width="25%" valign="middle"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule">XELODA<br/>(n=302)</th><BR>                                 <th styleCode="Lrule Rrule">5-FU/LV<br/>(n=303)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Overall Response Rate</content><BR>                                 </td><BR>                                 <td styleCode="Lrule" valign="bottom"/><BR>                                 <td styleCode="Lrule Rrule" valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(%, 95% C.I.)</td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">21 (16-26)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">11 (8-15)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(<content styleCode="italics">p</content>-value)</td><BR>                                 <td colspan="2" styleCode="Lrule Botrule Rrule">0.0014</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Time to Progression</content><BR>                                 </td><BR>                                 <td styleCode="Lrule" valign="bottom"/><BR>                                 <td styleCode="Lrule Rrule" valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(Median, days, 95% C.I.)</td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">128 (120-136)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">131 (105-153)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Hazard Ratio (XELODA/5-FU/LV)</td><BR>                                 <td colspan="2" styleCode="Lrule Rrule">0.99</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">95% C.I. for Hazard Ratio</td><BR>                                 <td colspan="2" styleCode="Lrule Botrule Rrule">(0.84-1.17)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Survival</content><BR>                                 </td><BR>                                 <td styleCode="Lrule" valign="bottom"/><BR>                                 <td styleCode="Lrule Rrule" valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(Median, days, 95% C.I.)</td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">380 (321-434)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">407 (366-446)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Hazard Ratio (XELODA/5-FU/LV)</td><BR>                                 <td colspan="2" styleCode="Lrule Rrule">1.00</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">95% C.I. for Hazard Ratio</td><BR>                                 <td colspan="2" styleCode="Lrule Botrule Rrule">(0.84-1.18)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t6" width="75%"><BR>                           <caption>Table 6 Efficacy of XELODA vs 5-FU/LV in Colorectal Cancer (Study 2)</caption><BR>                           <col align="left" width="50%" valign="middle"/><BR>                           <col align="center" width="25%" valign="middle"/><BR>                           <col align="center" width="25%" valign="middle"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule">XELODA<br/>(n=301)</th><BR>                                 <th styleCode="Lrule Rrule">5-FU/LV<br/>(n=301)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Overall Response Rate</content><BR>                                 </td><BR>                                 <td styleCode="Lrule" valign="bottom"/><BR>                                 <td styleCode="Lrule Rrule" valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(%, 95% C.I.)</td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">21 (16-26)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">14 (10-18)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(<content styleCode="italics">p</content>-value)</td><BR>                                 <td colspan="2" styleCode="Lrule Botrule Rrule">0.027</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Time to Progression</content><BR>                                 </td><BR>                                 <td styleCode="Lrule" valign="bottom"/><BR>                                 <td styleCode="Lrule Rrule" valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(Median, days, 95% C.I.)</td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">137 (128-165)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">131 (102-156)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Hazard Ratio (XELODA/5-FU/LV)</td><BR>                                 <td colspan="2" styleCode="Lrule Rrule">0.97</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">95% C.I. for Hazard Ratio</td><BR>                                 <td colspan="2" styleCode="Lrule Botrule Rrule">(0.82-1.14)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Survival</content><BR>                                 </td><BR>                                 <td styleCode="Lrule" valign="bottom"/><BR>                                 <td styleCode="Lrule Rrule" valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">(Median, days, 95% C.I.)</td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">404 (367-452)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">369 (338-430)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">Hazard Ratio (XELODA/5-FU/LV)</td><BR>                                 <td colspan="2" styleCode="Lrule Rrule">0.92</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">95% C.I. for Hazard Ratio</td><BR>                                 <td colspan="2" styleCode="Lrule Botrule Rrule">(0.78-1.09)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Figure 2 Kaplan-Meier Curve for Overall Survival of Pooled Data (Studies 1 and 2)<BR>                        <BR>                        <BR>                           <BR>                        <BR>                        XELODA was superior to 5-FU/LV for objective response rate in Study 1 and Study 2. The similarity of XELODA and 5-FU/LV in these studies was assessed by examining the potential difference between the two treatments. In order to assure that XELODA has a clinically meaningful survival effect, statistical analyses were performed to determine the percent of the survival effect of 5-FU/LV that was retained by XELODA. The estimate of the survival effect of 5-FU/LV was derived from a meta-analysis of ten randomized studies from the published literature comparing 5-FU to regimens of 5-FU/LV that were similar to the control arms used in these Studies 1 and 2. The method for comparing the treatments was to examine the worst case (95% confidence upper bound) for the difference between 5-FU/LV and XELODA, and to show that loss of more than 50% of the 5-FU/LV survival effect was ruled out. It was demonstrated that the percent of the survival effect of 5-FU/LV maintained was at least 61% for Study 2 and 10% for Study 1. The pooled result is consistent with a retention of at least 50% of the effect of 5-FU/LV. It should be noted that these values for preserved effect are based on the upper bound of the 5-FU/LV vs XELODA difference. These results do not exclude the possibility of true equivalence of XELODA to 5-FU/LV (see <BR>                              Table 5<BR>                           , <BR>                              Table 6<BR>                           , and <BR>                              Figure 2<BR>                           ). <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Breast Cancer<BR>                     <BR>                        XELODA has been evaluated in clinical trials in combination with docetaxel (Taxotere®) and as monotherapy.<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Breast Cancer Combination Therapy<BR>                     <BR>                        The dose of XELODA used in the phase 3 clinical trial in combination with docetaxel was based on the results of a phase 1 study, where a range of doses of docetaxel administered in 3-week cycles in combination with an intermittent regimen of XELODA (14 days of treatment, followed by a 7-day rest period) were evaluated. The combination dose regimen was selected based on the tolerability profile of the 75 mg/m2 administered in 3-week cycles of docetaxel in combination with 1250 mg/m2 twice daily for 14 days of XELODA administered in 3-week cycles. The approved dose of 100 mg/m2 of docetaxel administered in 3-week cycles was the control arm of the phase 3 study.<BR>                        XELODA in combination with docetaxel was assessed in an open-label, multicenter, randomized trial in 75 centers in Europe, North America, South America, Asia, and Australia. A total of 511 patients with metastatic breast cancer resistant to, or recurring during or after an anthracycline-containing therapy, or relapsing during or recurring within 2 years of completing an anthracycline-containing adjuvant therapy were enrolled. Two hundred and fifty-five (255) patients were randomized to receive XELODA 1250 mg/m2 twice daily for 14 days followed by 1 week without treatment and docetaxel 75 mg/m2 as a 1-hour intravenous infusion administered in 3-week cycles. In the monotherapy arm, 256 patients received docetaxel 100 mg/m2 as a 1-hour intravenous infusion administered in 3-week cycles. Patient demographics are provided in <BR>                              Table 7<BR>                           .<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t7" width="80%"><BR>                           <caption>Table 7 Baseline Demographics and Clinical Characteristics XELODA and Docetaxel Combination vs Docetaxel in Breast Cancer Trial</caption><BR>                           <col align="left" valign="bottom" width="50%"/><BR>                           <col align="center" valign="bottom" width="30%"/><BR>                           <col align="center" valign="bottom" width="20%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule">XELODA + Docetaxel<br/>(n=255)</th><BR>                                 <th styleCode="Lrule Rrule">Docetaxel<br/>(n=256)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold italics">Age</content> (median, years)</td><BR>                                 <td styleCode="Lrule Botrule">52</td><BR>                                 <td styleCode="Lrule Botrule Rrule">51</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold italics">Karnofsky PS</content> (median)</td><BR>                                 <td styleCode="Lrule Botrule">90</td><BR>                                 <td styleCode="Lrule Botrule Rrule">90</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold italics">Site of Disease</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Lymph nodes</td><BR>                                 <td styleCode="Lrule">121 (47%)</td><BR>                                 <td styleCode="Lrule Rrule">125 (49%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Liver</td><BR>                                 <td styleCode="Lrule">116 (45%)</td><BR>                                 <td styleCode="Lrule Rrule">122 (48%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Bone</td><BR>                                 <td styleCode="Lrule">107 (42%)</td><BR>                                 <td styleCode="Lrule Rrule">119 (46%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Lung</td><BR>                                 <td styleCode="Lrule">95 (37%)</td><BR>                                 <td styleCode="Lrule Rrule">99 (39%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Skin</td><BR>                                 <td styleCode="Lrule Botrule">73 (29%)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">73 (29%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold italics">Prior Chemotherapy</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Anthracycline<footnote>Includes 10 patients in combination and 18 patients in monotherapy arms treated with an anthracenedione</footnote><BR>                                 </td><BR>                                 <td styleCode="Lrule">255 (100%)</td><BR>                                 <td styleCode="Lrule Rrule">256 (100%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;5-FU</td><BR>                                 <td styleCode="Lrule">196 (77%)</td><BR>                                 <td styleCode="Lrule Rrule">189 (74%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Paclitaxel</td><BR>                                 <td styleCode="Lrule Botrule">25 (10%)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">22 (9%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold italics">Resistance to an Anthracycline</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;No resistance</td><BR>                                 <td styleCode="Lrule">19 (7%)</td><BR>                                 <td styleCode="Lrule Rrule">19 (7%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Progression on anthracycline therapy</td><BR>                                 <td styleCode="Lrule">65 (26%)</td><BR>                                 <td styleCode="Lrule Rrule">73 (29%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Stable disease after 4 cycles of anthracycline therapy</td><BR>                                 <td styleCode="Lrule" valign="bottom">41 (16%)</td><BR>                                 <td styleCode="Lrule Rrule" valign="bottom">40 (16%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Relapsed within 2 years of completion of anthracycline-adjuvant therapy</td><BR>                                 <td styleCode="Lrule" valign="bottom">78 (31%)</td><BR>                                 <td styleCode="Lrule Rrule" valign="bottom">74 (29%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Experienced a brief response to anthracycline therapy, with subsequent progression while on therapy or within 12 months after last dose</td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">51 (20%)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">50 (20%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold italics">No. of Prior Chemotherapy Regimens for Treatment of Metastatic Disease</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;0</td><BR>                                 <td styleCode="Lrule">89 (35%)</td><BR>                                 <td styleCode="Lrule Rrule">80 (31%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;1</td><BR>                                 <td styleCode="Lrule">123 (48%)</td><BR>                                 <td styleCode="Lrule Rrule">135 (53%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;2</td><BR>                                 <td styleCode="Lrule">43 (17%)</td><BR>                                 <td styleCode="Lrule Rrule">39 (15%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;3</td><BR>                                 <td styleCode="Lrule Botrule">0 (0%)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">2 (1%)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>XELODA in combination with docetaxel resulted in statistically significant improvement in time to disease progression, overall survival and objective response rate compared to monotherapy with docetaxel as shown in <BR>                              Table 8<BR>                           , <BR>                              Figure 3<BR>                           , and <BR>                              Figure 4<BR>                           .<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t8" width="75%"><BR>                           <caption>Table 8	Efficacy of XELODA and Docetaxel Combination vs Docetaxel Monotherapy</caption><BR>                           <col align="left" valign="top" width="28%"/><BR>                           <col align="center" valign="top" width="19%"/><BR>                           <col align="center" valign="top" width="19%"/><BR>                           <col align="center" valign="top" width="15%"/><BR>                           <col align="center" valign="top" width="19%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule" valign="top">Efficacy Parameter</th><BR>                                 <th styleCode="Lrule">Combination Therapy</th><BR>                                 <th styleCode="Lrule" valign="top">Monotherapy</th><BR>                                 <th styleCode="Lrule" valign="top">p-value</th><BR>                                 <th styleCode="Lrule Rrule">Hazard Ratio</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Time to Disease Progression</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule"><BR>                                    <content styleCode="bold">Median Days</content><BR>                                 </td><BR>                                 <td styleCode="Lrule">186</td><BR>                                 <td styleCode="Lrule">128</td><BR>                                 <td styleCode="Lrule">0.0001</td><BR>                                 <td styleCode="Lrule Rrule">0.643</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold">95% C.I.</content><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule">(165-198)</td><BR>                                 <td styleCode="Lrule Botrule">(105-136)</td><BR>                                 <td styleCode="Lrule Botrule"/><BR>                                 <td styleCode="Lrule Botrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">Overall Survival</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule"><BR>                                    <content styleCode="bold">Median Days</content><BR>                                 </td><BR>                                 <td styleCode="Lrule">442</td><BR>                                 <td styleCode="Lrule">352</td><BR>                                 <td styleCode="Lrule">0.0126</td><BR>                                 <td styleCode="Lrule Rrule">0.775</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold">95% C.I.</content><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule">(375-497)</td><BR>                                 <td styleCode="Lrule Botrule">(298-387)</td><BR>                                 <td styleCode="Lrule Botrule"/><BR>                                 <td styleCode="Lrule Botrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold">Response Rate<footnote>The response rate reported represents a reconciliation of the investigator and IRC assessments performed by the sponsor according to a predefined algorithm.</footnote><BR>                                    </content><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule">32%</td><BR>                                 <td styleCode="Lrule Botrule">22%</td><BR>                                 <td styleCode="Lrule Botrule">0.009</td><BR>                                 <td styleCode="Lrule Botrule Rrule">NA<footnote>NA = Not Applicable</footnote><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Figure 3 Kaplan-Meier Estimates for Time to Disease Progression XELODA and Docetaxel vs Docetaxel<BR>                        <BR>                        <BR>                           <BR>                        <BR>                        <BR>                           Figure 4 Kaplan-Meier Estimates of Survival XELODA and Docetaxel vs Docetaxel<BR>                        <BR>                        <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Breast Cancer Monotherapy<BR>                     <BR>                        The antitumor activity of XELODA as a monotherapy was evaluated in an open-label single-arm trial conducted in 24 centers in the US and Canada. A total of 162 patients with stage IV breast cancer were enrolled. The primary endpoint was tumor response rate in patients with measurable disease, with response defined as a ≥50% decrease in sum of the products of the perpendicular diameters of bidimensionally measurable disease for at least 1 month. XELODA was administered at a dose of 1255 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles. The baseline demographics and clinical characteristics for all patients (n=162) and those with measurable disease (n=135) are shown in <BR>                              Table 9<BR>                           . Resistance was defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant chemotherapy regimen.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t9" width="75%"><BR>                           <caption>Table 9 Baseline Demographics and Clinical Characteristics Single-Arm Breast Cancer Trial</caption><BR>                           <col align="left" width="45%" valign="middle"/><BR>                           <col align="center" width="30%" valign="middle"/><BR>                           <col align="center" width="25%" valign="middle"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule">Patients With Measurable Disease<br/>(n=135)</th><BR>                                 <th styleCode="Lrule Rrule" valign="bottom">All Patients<br/>(n=162)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold italics">Age</content> (median, years)</td><BR>                                 <td styleCode="Lrule Botrule">55</td><BR>                                 <td styleCode="Lrule Botrule Rrule">56</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule"><BR>                                    <content styleCode="bold italics">Karnofsky PS</content><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule">90</td><BR>                                 <td styleCode="Lrule Botrule Rrule">90</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold italics">No. Disease Sites</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;1-2</td><BR>                                 <td styleCode="Lrule">43 (32%)</td><BR>                                 <td styleCode="Lrule Rrule">60 (37%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;3-4</td><BR>                                 <td styleCode="Lrule">63 (46%)</td><BR>                                 <td styleCode="Lrule Rrule">69 (43%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;&gt;5</td><BR>                                 <td styleCode="Lrule Botrule">29 (22%)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">34 (21%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold italics">Dominant Site of Disease</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Visceral<footnote>Lung, pleura, liver, peritoneum</footnote><BR>                                 </td><BR>                                 <td styleCode="Lrule">101 (75%)</td><BR>                                 <td styleCode="Lrule Rrule">110 (68%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Soft Tissue</td><BR>                                 <td styleCode="Lrule">30 (22%)</td><BR>                                 <td styleCode="Lrule Rrule">35 (22%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Bone</td><BR>                                 <td styleCode="Lrule Botrule">4 (3%)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">17 (10%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold italics">Prior Chemotherapy</content><BR>                                 </td><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Paclitaxel</td><BR>                                 <td styleCode="Lrule">135 (100%)</td><BR>                                 <td styleCode="Lrule Rrule">162 (100%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Anthracycline<footnote ID="table9foot2">Includes 2 patients treated with an anthracenedione</footnote><BR>                                 </td><BR>                                 <td styleCode="Lrule">122 (90%)</td><BR>                                 <td styleCode="Lrule Rrule">147 (91%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;5-FU</td><BR>                                 <td styleCode="Lrule">110 (81%)</td><BR>                                 <td styleCode="Lrule Rrule">133 (82%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Resistance to Paclitaxel</td><BR>                                 <td styleCode="Lrule">103 (76%)</td><BR>                                 <td styleCode="Lrule Rrule">124 (77%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Resistance to an Anthracycline<footnoteRef IDREF="table9foot2"/><BR>                                 </td><BR>                                 <td styleCode="Lrule">55 (41%)</td><BR>                                 <td styleCode="Lrule Rrule">67 (41%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;Resistance to both Paclitaxel<br/>&#160;&#160;&#160;&#160;and an Anthracycline<footnoteRef IDREF="table9foot2"/><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule" valign="bottom">43 (32%)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">51 (31%)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Antitumor responses for patients with disease resistant to both paclitaxel and an anthracycline are shown in <BR>                              Table 10<BR>                           .<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t10" width="75%"><BR>                           <caption>Table 10	Response Rates in Doubly-Resistant Patients Single-Arm Breast Cancer Trial</caption><BR>                           <col align="center" width="50%" valign="middle"/><BR>                           <col align="center" width="50%" valign="middle"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule Rrule">Resistance to Both Paclitaxel and an Anthracycline<br/>(n=43)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">CR</td><BR>                                 <td styleCode="Lrule Botrule Rrule">0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">PR<footnote ID="table10foot1">Includes 2 patients treated with an anthracenedione</footnote><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule Rrule">11</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">CR + PR<footnoteRef IDREF="table10foot1"/><BR>                                 </td><BR>                                 <td styleCode="Lrule Botrule Rrule">11</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Response Rate<footnoteRef IDREF="table10foot1"/><BR>                                    <br/>(95% C.I.)</td><BR>                                 <td styleCode="Lrule Botrule Rrule">25.6%<br/>(13.5, 41.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">Duration of Response,<footnoteRef IDREF="table10foot1"/><BR>                                    <br/>Median in days<footnote>From date of first response</footnote><BR>                                    <br/>(Range)</td><BR>                                 <td styleCode="Lrule Botrule Rrule" valign="bottom">154<br/>(63-233)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>For the subgroup of 43 patients who were doubly resistant, the median time to progression was 102 days and the median survival was 255 days. The objective response rate in this population was supported by a response rate of 18.5% (1 CR, 24 PRs) in the overall population of 135 patients with measurable disease, who were less resistant to chemotherapy (see <BR>                              Table 9<BR>                           ). The median time to progression was 90 days and the median survival was 306 days.<BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>